Eye­ing block­buster mi­graine mar­ket, Al­ler­gan un­loads sec­ond set of pos­i­tive PhI­II re­sults for ubro­gepant

Al­ler­gan $AGN rolled out its sec­ond wave of pos­i­tive Phase III da­ta for its oral mi­graine drug ubro­gepant, which nailed its end­points in the high­er dose but failed to elic­it much ef­fect in the low­er amount.

The drug was test­ed in two dos­es: 25 mg and 50 mg along­side a place­bo in 1,686 pa­tients with sin­gle mi­graine at­tacks. The 50 mg dose of ubro­gepant showed a sta­tis­ti­cal­ly sig­nif­i­cant per­cent­age of pa­tients get pain re­lief at 2 hours, sus­tained pain re­lief from 2 to 24 hours, and sus­tained pain free­dom from 2 to 24 hours af­ter the ini­tial dose as com­pared to place­bo (p=0.0129 for each of these end­points). More pa­tients on the high­er dose al­so showed an ab­sence of pho­to­pho­bia (light sen­si­tiv­i­ty), and phono­pho­bia (noise sen­si­tiv­i­ty).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER